Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) - Investment analysts at Lifesci Capital issued their Q3 2025 earnings per share estimates for shares of Soleno Therapeutics in a research note issued to investors on Wednesday, September 10th. Lifesci Capital analyst K. Dellorusso expects that the company will earn ($0.01) per share for the quarter. Lifesci Capital currently has a "Strong-Buy" rating on the stock. The consensus estimate for Soleno Therapeutics' current full-year earnings is ($3.72) per share. Lifesci Capital also issued estimates for Soleno Therapeutics' Q4 2025 earnings at $0.18 EPS, FY2025 earnings at ($0.87) EPS, Q1 2026 earnings at $0.25 EPS, Q2 2026 earnings at $0.37 EPS, Q3 2026 earnings at $0.63 EPS, Q4 2026 earnings at $0.91 EPS and FY2026 earnings at $2.91 EPS.
Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.53) by $0.44. The firm had revenue of $32.66 million during the quarter, compared to the consensus estimate of $3.91 million.
A number of other research analysts have also recently commented on SLNO. Guggenheim reiterated a "buy" rating and issued a $106.00 price target on shares of Soleno Therapeutics in a research note on Wednesday, August 27th. HC Wainwright restated a "buy" rating and issued a $110.00 price objective (up from $100.00) on shares of Soleno Therapeutics in a report on Monday, August 18th. Wall Street Zen upgraded Soleno Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, July 26th. Oppenheimer increased their price objective on Soleno Therapeutics from $105.00 to $110.00 and gave the company an "outperform" rating in a report on Thursday, August 7th. Finally, TD Cowen started coverage on Soleno Therapeutics in a report on Monday, June 23rd. They issued a "buy" rating and a $110.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating and eleven have given a Buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $115.09.
Read Our Latest Report on Soleno Therapeutics
Soleno Therapeutics Price Performance
Shares of SLNO traded down $3.10 during trading hours on Friday, reaching $53.62. The stock had a trading volume of 3,249,912 shares, compared to its average volume of 1,619,524. Soleno Therapeutics has a 12 month low of $41.50 and a 12 month high of $90.32. The stock has a market capitalization of $2.85 billion, a PE ratio of -12.95 and a beta of -2.71. The company has a debt-to-equity ratio of 0.21, a quick ratio of 15.01 and a current ratio of 15.13. The company's 50-day moving average is $77.05 and its two-hundred day moving average is $72.01.
Insiders Place Their Bets
In other Soleno Therapeutics news, insider Patricia C. Hirano sold 3,830 shares of the stock in a transaction dated Tuesday, July 1st. The stock was sold at an average price of $82.76, for a total transaction of $316,970.80. Following the completion of the sale, the insider directly owned 13,206 shares in the company, valued at approximately $1,092,928.56. This trade represents a 22.48% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 6.40% of the company's stock.
Institutional Trading of Soleno Therapeutics
A number of large investors have recently bought and sold shares of the business. Osaic Holdings Inc. grew its holdings in Soleno Therapeutics by 97.7% during the 2nd quarter. Osaic Holdings Inc. now owns 856 shares of the company's stock worth $72,000 after acquiring an additional 423 shares during the period. Orion Porfolio Solutions LLC acquired a new stake in Soleno Therapeutics during the 2nd quarter worth about $215,000. Nomura Holdings Inc. grew its holdings in Soleno Therapeutics by 156.7% during the 2nd quarter. Nomura Holdings Inc. now owns 3,644 shares of the company's stock worth $305,000 after acquiring an additional 10,075 shares during the period. Castleark Management LLC acquired a new stake in Soleno Therapeutics during the 2nd quarter worth about $2,919,000. Finally, Headlands Technologies LLC acquired a new stake in Soleno Therapeutics during the 2nd quarter worth about $204,000. 97.42% of the stock is currently owned by institutional investors and hedge funds.
Soleno Therapeutics Company Profile
(
Get Free Report)
Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.
Further Reading
Before you consider Soleno Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Soleno Therapeutics wasn't on the list.
While Soleno Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
